News | October 28, 2008

Cardiac Biomarker Soluble ST2 Offers Value in the Care of Heart Failure Patients

October 29, 2008 - Critical Diagnostics today announced the publication of a research paper and an accompanying editorial comment further refining the clinical value and risk of mortality prediction power of the cardiac biomarker soluble ST2 (sST2).

The research paper, “Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients with Acute Heart Failure” and editorial comment “Serum Soluble ST2 as a Biochemical Marker of Acute Heart Failure” was published in the Journal of the American College of Cardiology, Oct. 28. The result of this latest study expands understanding of this biomarker in patients with acute destabilized heart failure (ADHF), further refining the clinical value of sST2 in these patients.

The study analyzed 346 patients diagnosed with ADHF derived from two previously reported prospective clinical trials of dyspneic emergency department patients. This study confirms previously reported results that sST2 powerfully predicts mortality, independent of established clinical and biochemical predictors in this setting. Senior author on this paper, Dr. James L. Januzzi, associate professor of medicine at Harvard Medical School, and physician in the division of cardiology at the Massachusetts General Hospital where he is also the chief of the coronary care unit, added, “What is interesting to us are the emerging data linking sST2 to a wide range of cardiovascular diseases, including coronary artery disease and heart failure. On a biological level ST2 appears to play a pivotal role in the complications stemming from both states, which raises the question of an entirely new avenue of exploration for cardiac therapeutics. Furthermore, the clinical value of sST2 measurement appears established - together with testing for conventional markers such as natriuretic peptides, sST2 adds clear, solid value for assessing risk; with this better ability to recognize risk will follow more opportunity for timely and correct intervention, and the hope to better reduce the potential for complications.”

Cardiovascular disease is the leading cause of death in the U.S. and the incidence of heart failure, as a form of cardiovascular disease, is increasing. The research described in this paper confirms that sST2 is a powerful and accurate biomarker for prediction of near term mortality in ADHF patients and its clinical use may lead to improvements in patient care.

For more information:,

Related Content

Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
Overlay Init